07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chondroitin sulfate proteoglycans (CSPG); versican (VCAN)

Autoimmune disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies identified a UDP-N-acetylglucosamine-based inhibitor of CSPG synthesis that could help treat MS. Chemical synthesis of UDP-N-acetylglucosamine analogs and testing in mouse and human astrocyte-based assays of...
08:00 , Dec 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Variant surface antigen 2 chondroitin sulphate A (VAR2CSA); chondroitin sulfate proteoglycans (CSPG)

Cancer INDICATION: Cancer Patient sample, cell culture and mouse studies suggest VAR2CSA conjugated to cytotoxic agents could help treat cancer. In patients with various types of epithelial cancers, bone sarcomas or soft tissue sarcomas, binding between VAR2CSA...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Chondroitin sulfate proteoglycan (CSPG) Rat studies suggest lentivirus-delivered, mammalian-optimized chondroitinase ABC (ChABC)...
08:00 , Mar 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB); NTRK3 (TrkC); chondroitin sulfate proteoglycan (CSPG) ...
07:00 , Mar 22, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Chondroitin sulfate proteoglycan (CSPG); chondroitin sulphate E (CS-E) In vitro and mouse studies suggest inhibiting...
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Protein tyrosine phosphatase receptor type F (PTPRF; LAR) Rodent studies suggest blocking the...
07:00 , Jul 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Chondroitin sulfate proteoglycan (CSPG) Rat studies suggest a peripheral nerve autograft plus treatment...
07:00 , Jul 1, 2010 |  BC Innovations  |  Targets & Mechanisms

Neuraminidase for spinal cord injury

Researchers at The Johns Hopkins University School of Medicine have shown that treatment with a recombinant bacterial neuraminidase can promote the recovery of motor and autonomic function in a rat model of spinal cord contusion...
07:00 , Jun 17, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Neuraminidase (NEU1; SIAL1) A study in rats suggests that Vibrio cholerae neu1 could...
07:00 , Apr 15, 2010 |  BC Innovations  |  Targets & Mechanisms

Axon-regenerating small molecules

Researchers at the University of Miami Miller School of Medicine have identified compounds that can overcome the two main types of signals that inhibit axon growth in a damaged CNS.1 The compounds reversed the effects...